CAPR FDA extends deramiocel BLA review target to November 22, 2026
Capricor Therapeutics says the FDA has extended the PDUFA target action date for deramiocel BLA review to November 22, 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.